Summary of COVID-19 inosine pranobex studies

1. Jayanthi et al., Efficacy and Safety of Inosine Pranobex in COVID‐19 Patients: A Multicenter Phase 3 Randomized Double‐Blind, Placebo‐Controlled Trial

414 patient inosine pranobex early treatment RCT: 27% improved recovery (p=0.003) and 33% greater improvement (p=0.0005).
RCT 416 mild-to-moderate COVID-19 patients (both hospitalized and non-hospitalized) showing improved recovery with inosine pranobex.
Sep 2022, Advanced Therapeutics, https://onlinelibrary.wiley.com/doi/10.1002/adtp.202200159, https://c19p.org/jayanthi

2. Veselý et al., Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry

127,038 patient inosine pranobex early treatment study: 46% lower mortality (p=0.11).
Retrospective 67,841 inosine pranobex recipients matched 1:2 with 135,682 controls from the Czech national registry, showing significantly reduced COVID-19 mortality with treatment. Negative control outcome analyses (non-COVID mortality, cardiovascular mortality, external-cause mortality) showed no benefit, suggesting the effect is not purely a healthy-user bias. Authors note that treatment was prescribed preferentially to higher-risk patients, yet recipients still showed lower mortality, which strengthens the apparent benefit but cannot fully exclude unmeasured confounders.
Mar 2026, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971226001542, https://c19p.org/vesely